Compounding pharmacy bench with medicine vials and a cease-and-desist letter

Compounding Pharmacy Attorney Guidance Amid Novo Nordisk Cease‑and‑Desist Push

Compounding pharmacy attorney firms are receiving a surge of cease‑and‑desist letters from Novo Nordisk targeting compounding pharmacies, outsourcing facilities, and telemedicine providers who distributed compounded semaglutide after the FDA ended the shortage designation in February‑March 2025.

Why Pharma Giants Are Now in Enforcement Mode

When the FDA officially determined that the shortages for Wegovy and Ozempic were resolved—removing semaglutide from its drug shortage list—Novo Nordisk and other manufacturers gained legal grounds to stop unapproved versions under Section 503A/503B. Novo Nordisk has filed over 100 lawsuits nationwide and dispatched letters warning of legal consequences if compounding continues.

Legal Risks for Healthcare Providers

These cease‑and‑desist letters are preliminary legal notices—not lawsuits—but ignoring them can escalate matters swiftly. Providers who trade in compounded semaglutide post‑shortage risk:

• Trademark/patent infringement and false marketing claims.
• Federal enforcement if 503B outsourcers haven’t ceased production by May 22, 2025; 503A must stop by April 22 or when court decisions issue.

Action Steps for Clinics, Pharmacies, and Hospitals

Outsourcing facilities and pharmacies facing these letters should:

1. Immediately pause all semaglutide compounding.
2. Consult a pharmacy FDA compliance lawyer or pharmacy regulatory attorney.

A tailored response can help defend against allegations of unapproved drug manufacturing, misbranding, or deceptive practices.

Your Defense Starts with Expert Legal Counsel

You’re not alone in this. No one expects to get that knock at the door—but timely legal counsel can help. Our team offers free 15‑minute consultations to assess your situation and guide you through compliance, enforcement defense, and litigation support.

Learn how a seasoned outsourcing facility legal representation attorney can pivot your operations into compliance and reduce liability.

Ready to Respond? Contact Us

Don’t wait. Call us at (305) 358‑4500 or email info@vitalehealthlaw.com for prompt counsel—whether it’s crafting responses, negotiating delays, or defending against legal action.

Stay Compliant, Stay Protected

Now that semaglutide shortages are formally over, you must operate within legal FDA limits. Engaging proactive legal guidance ensures your facility stays in the clear.

Urgent Legal Shield for Compounding Pharmacies

Act decisively with professional legal support to handle pharmacy litigation support, defend against manufacturer enforcement actions, and secure compliant operations. Call today for your free consultation.

Frequently Asked Questions

1. Is compounding semaglutide still allowed for research purposes?

Only under strict regulatory controls. If used in clinical research, it must comply with FDA Investigational New Drug (IND) protocols. Commercial sales are not permitted post-shortage.

2. What should I do if I’ve already received a cease-and-desist letter?

Do not respond without counsel. Contact a pharmacy regulatory attorney immediately to evaluate your exposure and develop a strategic legal response.

3. Are telemedicine platforms at risk even if they’re not compounding drugs themselves?

Yes. Platforms promoting or facilitating access to compounded semaglutide may face claims of contributory liability or deceptive advertising.

4. Can a pharmacy still compound semaglutide analogs or salts not covered by the FDA?

Possibly—but it’s a legal gray area. Many versions still fall under Novo Nordisk’s IP protections. A risk assessment with legal review is essential before proceeding.

5. Will state boards of pharmacy get involved in these enforcement actions?

Yes, especially if the pharmacy’s conduct violates federal law or state licensing requirements. Multiple agencies may coordinate enforcement or disciplinary action.

Scroll to Top